BLU-285—the breakthrough in treatment of patients with aggressive systemic mastocytosis and gastrointestinal stromal tumor

In a recent phase I clinical trial an international consortium of gastrointestinal stromal tumors (GIST) researchers from Portland (USA), Leuven (Belgium) and Boston (USA) together with people from the drug developing company Blueprint Medicine report on a new promising small-molecule inhibitor for treating patients with aggressive systemic mastocytosis (SM) and GISTs.